Summary Pancreatitis-associated protein I (PAP I) is a secretory protein first described as an acute phase reactant during acute pancreatitis. Recently, induction of the PAP I gene was also described in liver during hepatocarcinogenesis. To investigate the molecular mechanisms of this induction, we used constructs carrying progressive deletions of the PAP I promoter fused to the CAT gene. We showed that the silencer conferring tissue specificity on the PAP I gene was inactive in hepatoma cells. Then, in an in vitro transcription system, we compared the transcription capacity of nuclear extracts from normal liver and HepG2 cells on constructs containing the silencer. The results confirmed that a trans-acting factor interacting with the PAP I silencer was present in liver cells and absent from hepatoma cells. On the other hand, immunohistochemistry showed that PAP I was expressed in a limited number of transformed hepatocytes. It was concluded that expression of PAP I in hepatocarcinoma occurred through inactivation of its silencer element and was not concomitant in all malignant cells. On that basis, we assayed PAP I in serum from patients with chronic hepatitis, liver cirrhosis or hepatocarcinoma. PAP I levels were normal in chronic active or persistent hepatitis, significantly higher in cirrhosis and strongly elevated in hepatocarcinoma. Because those clinical entities often develop in that sequence, serum PAP I appeared as a potential marker of hepatocarcinoma development.
Pancreatitis-associated protein (PAP) is a secretory protein present in small amounts in normal pancreas and rapidly overexpressed during the acute phase of pancreatitis (Keim et al., 1991; Iovanna et al., 1991a) . It was characterised as a novel serum indicator of the course of acute pancreatitis (lovanna et al., 1994) . It was shown recently that PAP belongs to a family of structurally related proteins whose genes have similar organisation and the same chromosomal location, suggesting that they are derived from a common ancestor Frigerio et al., 1993; Dusetti et al., 1995a; Stephanova et al., 1996) . In this family, we described three PAPs, the original one becoming PAP I, and two reg/lithostathines (Giorgi et al., 1989; Bartoli et al., 1993) . Their sequence contains a carbohydrate recognition domain (CRD), typical of calcium-dependent lectins Drickamer, 1988) . They show among lectins the peculiar features of being secretory proteins and having a single CRD. In Drickamer's classification, they appear now as the group VII or free CRD lectins (Drickamer, 1993) .
Expression of PAP I is not restricted to the pancreas, upon induction of pancreatitis. It is also constitutively expressed by the epithelial cells of the small intestine lovanna et al., 1993; Masciotra et al., 1995; Kamimura et al., 1992; Itho and Teraoka, 1993; Chakraborty et al., 1995) and secreted by rat pituitary cells upon induction by growthhormone-releasing hormone (Tachibana et al., 1988; Katsumata et al., 1995) . In addition, Lasserre et al. (1992) , using differential screening of a human hepatocellular carcinoma cDNA library, have cloned a mRNA, called HIP, which is identical to PAP I. They found that PAP I was expressed at high levels in 7 of 29 hepatocellular carcinomas but not in normal or fetal liver.
Little is known about the pathophysiological significance of PAP I expression. It might be associated with regulation of cell proliferation, as suggested in the pituitary (Tachibana et al., 1988) . This is supported by its constitutive expression in the intestinal epithelium, where cellular turnover is very fast, and by the triggering of the expression of the PAP-related protein reg during islet cell regeneration (Terazano et al., 1988) . By contrast, PAP expression in the exocrine pancreas could not be related to regeneration. It was typical of an acute phase reactant, and topological analysis of the PAP I gene showed the presence in the promoter of several cisacting elements responding to inflammatory mediators such as cytokines (Dusetti et al., 1994a (Dusetti et al., , 1995b .
The report of PAP I expression in liver during carcinogenesis was the first evidence that the PAPs were involved in cancer. This observation greatly extended the potential importance of this family of proteins in human pathology. As a result, the mechanism of PAP I induction warranted analysis in hepatocarcinogenesis. We have demonstrated that PAP I was synthesised in a fraction of the transformed hepatocytes, and we localised within the promoter of the PAP I gene a suppressor region whose activity was inhibited in hepatoma cells. Also, because PAP I is a secretory protein that may leak into blood, as it does during acute pancreatitis (Iovanna et al., 1994) , we decided to determine whether serum PAP I concentrations would reflect evolution of the disease, and we have showed that it increased with hepatocarcinoma development.
Materials and methods

Molecular studies
Cell culture HepG2 hepatoma and Rat2 fibroblast cells were purchased from the American Type Culture Collection. HepG2 cells were routinely cultivated at 37°C in a 5% carbon dioxide, 95% air atmosphere in Dulbecco's modified Eagle medium containing 10% (v/v) fetal calf serum Transfection assays CAT reporter gene constructs All DNA constructs were generated by polymerase chain reaction (PCR) using the plasmid P/P as a template . That plasmid is a pBluescript KS', in which was subcloned a 2859 bp PstIPstI genomic DNA fragment containing the PAP I gene including 1253 nucleotides of the promoter. Accuracy of PCR was increased by using low dNTP concentrations (Ehlen and Dubeau, 1989) (Luckow and Schutz, 1987) , which contains the CAT gene driven by the herpes simplex virus thymidine kinase promoter.
DNA purification Plasmid DNA was purified with the Quiagen plasmid kit (Diagen, Hilden, Germany), and the DNA concentration was measured by spectrophotometry. Sequences were verified by the chain termination method, using the T7 Sequencing Kit (Pharmacia). Plasmids were also checked for purity, concentration, supercoiling and restriction pattern using agarose gel electrophoresis.
Cell transfection and CAT assays Fifty to sixty per cent confluent HepG2 and Rat2 cells in 100 mm Petri dishes were transfected using the calcium phosphate DNA co-precipitation method (Graham and van der Eb, 1973) . Culture medium was changed 3 h before transfection. The transfection mixture contained 15 Mg of test plasmid and 5 Mg of pCMV/,B-gal plasmid (Promega). Four hours after the addition of the DNA, cells were treated with 20% (v/v) glycerol for 2 min, washed with serum-free medium and transferred to serum-containing medium. Each construct was transfected in triplicate. In all cases, at least two separate plasmid preparations were tested in the transfection experiments. At 48-72 h after transfection, cell extracts were prepared using the reporter lysis buffer (Promega). CA T activity was determined using a phase extraction procedure (Seed and Sheen, 1988) , and P-galactosidase assays were performed essentially as previously described (Sambrook et al., 1989 (Rosenthal, 1987) . To check the cell specific activity of the -180/ -118 region of the PAP I promoter, this fragment was inserted upstream from the thymidine kinase promoter (Figure 2, (Figure 5a and b). In addition, transferred cells forming bile duct-like structures could also be occasionally stained (Figure 5c ), whereas other cell types, such as endothelial cells, were negative. Appropriate controls established the specificity of the reaction.
PAP serum levels Figure 6 shows the distribution of PAP values in the five study groups. Values in patients with chronic active or persistent hepatitis were not different from those of controls (median values at 38 and 39, compared with 34 ,ug 1-'). A significant increase, compared with controls, was observed in patients with liver cirrhosis (P<0.01, median value at 43 ,ug 1') with 4 out of 25 patients showing values over the upper threshold of normal values (90 jug 1-. The increase was much more significant in patients with hepatocarcinoma compared with controls and also cirrhotic patients (P<0.0001). In the HCC group, 64% of patients had PAP values above the normal threshold. Table I shows correlations between PAP levels and a series of parameters of liver function. There was a negative correlation between PAP and albumin of prothrombin levels, two indicators of protein synthesis in liver (P<0.0001 and P<0.01 respectively) or the number of circulating platelets (P<0.004). There was a direct correlation with y-globulin levels (P<0.03). In contrast, there was no significant correlation between PAP I serum concentrations and the parameters of cytolysis or serum levels of AFP (Table I and Figure 7 ).
Discussion
In the decade that followed the original characterisation of PAP I in rat pancreatic juice, the PAP family has extended to more than a dozen proteins whose expression occurs in many tissues and shows in these tissues different patterns of regulation. Such ubiquity, suggesting an important physiological function, aroused further interest when PAP I expression was found associated with pathological situations. Important induction was reported in pancreas during development of acute pancreatitis (lovanna et al., 1991a, b) , and, more recently, PAP I was described in liver during hepatocarcinogenesis (Lasserre et al., 1992) . The molecular mechanism of PAP I induction during the acute phase of pancreatitis has been extensively analysed (Dusetti et al.,
1994a, b). The promoter allows expression in normal pancreas, the tissue specificity being controlled by a silencer element turned off in pancreas by trans-acting cellular factors (Dusetti et al., 1995c) . Activity remains very low in normal tissue and induction is triggered by factors released during inflammation, such as cytokines, which is typical of acutephase reactants. Members of the PAP family are apparently the only pancreatic proteins that are always induced during pancreatitis Dusetti et al., 1995a; lovanna et al., 1991a; Rouquier et al., 1991) . The available information on PAP I expression during liver carcinogenesis suggested a more complex situation.
Other proteins, such as the AFP, were also induced. However, those proteins appeared to be expressed in consequence of the dedifferentiation of the hepatocytes because they were also found in the regenerating liver and during liver development (Tsutsumi et al., 1994) . By contrast, PAP I was not observed in fetal or regenerating liver (Lasserre et al., 1992) , suggesting a mechanism specifically related to carcinogenesis. Activation of the PAP I gene expression during carcinogenesis does not seem to be liver specific, because most of the studied cholangiocarcinoma and stomach cancers also expressed high levels of PAP I mRNA. However, PAP I mRNA expression is not a constant factor during carcinogenes. For example, we have found no induction in any of 12 colorectal carcinoma (unpublished results).
Because control of tissue-specific expression by a silencer is an elaborate mechanism, we made the hypothesis that it had been lost during hepatic carcinogenesis. This was tested in hepatoma cells transfected with progressive deletions of the PAP I promoter fused to the reporter gene CAT. The silencer, corresponding to the region between nt -118 and -180 of the promoter, prevented CAT expression in fibroblast (Rat2) cells, as expected, and was indeed inactive in hepatoma (HepG2) cells in which abundant CA T expression was observed (Figures 1 and 2 ). This experiment would have been optimally controlled if, in normal hepatocytes, no CA T expression was obtained with the Figure 6 Serum PAP I concentrations. Serum PAP I concentration was measured in patients suffering from chronic persistent hepatitis (CPH) (n =40), chronic active hepatitis (CAH) (n= 41), liver cirrhosis (Ci) (n = 25), hepatocarcinoma (HCC) (n = 34) or in healthy asymptomatic subjects (Co) (n = 67 Figure 3 , the globulin remain to be explored. There was however no icts was absent when correlation between PAP I and AFP serum concentrations in also from normal these patients (Figure 7) 
